       Document 0359
 DOCN  M9460359
 TI    An interim report on the effect of natural human interferon alpha
       (IFN-alpha) lozenges in patients seropositive for the human
       immunodeficiency virus type 1 (HIV-1).
 DT    9404
 AU    Babiuch L; Mian M; Kaminska E; Szymanska B; Georgiades JA; Department of
       Acquired Immune Deficiency Syndrome, Institute of; Infectious and
       Parasitic Diseases, Warsaw, Poland.
 SO    Arch Immunol Ther Exp (Warsz). 1993;41(3-4):213-9. Unique Identifier :
       AIDSLINE MED/94175721
 AB    Oral mucosal administration of natural human interferon alpha
       (IFN-alpha) lozenges has previously been applied to the treatment of
       HIV-1 seropositive patients with benefits including weight gain and
       amelioration of clinical signs and symptoms of disease. These previous
       studies have been of short duration and employed treatment at a constant
       dosage. In this interim report, we describe the positive effects of
       long-term administration of IFN-alpha lozenges given in increasing
       dosages over the time. Forty adult patients positive for HIV-1 by ELISA
       and Western Blot have been enrolled in an ongoing, open-label study.
       Patients have received IFN-alpha lozenges at dosages ranging from 75-600
       IU administered once daily into the oral cavity to promote oral mucosal
       contact. Patients have been treated for variable periods, ranging from
       19 days to over 700 days. A group of untreated and unmatched patients,
       positive for HIV-1 by ELISA and Western Blot, were also followed during
       this study. At the time of this interim report, only 18 patients had
       received long-term treatment (more than 168 days with one or more
       increases in dosage). Five of the 18 patients died; one committed
       suicide. Two died due to complications of Kaposi sarcoma and another two
       died of HIV-related causes. The remaining 13 patients have exhibited a
       significantly smaller mean monthly decrease in CD4+ cells than the
       untreated but unmatched patients monitored during the same time period
       (P < or = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Administration, Oral  Adult  Female  Human  HIV Seropositivity/*THERAPY
       HIV-1/*IMMUNOLOGY  Interferon-alpha/ADMINISTRATION & DOSAGE/*THERAPEUTIC
       USE  Leukocyte Count  Male  Middle Age  T4 Lymphocytes  CLINICAL TRIAL
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

